| P50 | author | L. Douglas Case | Q87811272 |
| P2093 | author name string | A William Blackstock | |
| | Paul Savage | |
| | Douglas R White | |
| | Shannon K Tomlinson | |
| | Susan A Melin | |
| | Vetta Higgs | |
| P2860 | cites work | Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial | Q71117223 |
| | Relationship of cellular folate cofactor pools to the activity of 5-fluorouracil | Q71245137 |
| | Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1 | Q71261810 |
| | Phase II study of UFT plus leucovorin in colorectal cancer | Q71934552 |
| | Effect of modulators on 5-fluorouracil metabolite patterns in murine colon carcinoma determined by in vitro 19F nuclear magnetic resonance spectroscopy | Q72092495 |
| | Addition of leucovorin in modulation of 5-fluorouracil with methotrexate: potentiating or reversing effect? | Q72282496 |
| | Chemotherapy for colorectal cancer | Q72305700 |
| | Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project | Q72377577 |
| | Double modulation of 5-fluorouracil by leucovorin and low-dose methotrexate in advanced colorectal cancer | Q73107307 |
| | Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines | Q73177853 |
| | Concurrent modulation of 5-fluorouracil with methotrexate and L-leucovorin: an effective and moderately toxic regimen for the treatment of advanced colorectal carcinoma. A multicenter phase II study of the Southern Italy Cooperative Oncology Group | Q73696560 |
| | Double modulation of 5-fluorouracil by methotrexate and high-dose L-leucovorin in advanced colorectal cancer | Q74305782 |
| | Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer | Q74604684 |
| | A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma | Q74635392 |
| | Irinotecan in the first-line treatment of colorectal cancer | Q77190952 |
| | Pharmacokinetics of recombinant human interferon-alpha 2a combined with 5-fluorouracil in patients with advanced colorectal carcinoma | Q33504403 |
| | Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen | Q34505635 |
| | Enhanced 5-fluorouracil cytotoxicity and elevated 5-fluoronucleotides in the rat Walker carcinosarcoma following methotrexate pre-treatment: a 19F-MRS study in vivo | Q35993564 |
| | 5-fluorouracil-methotrexate synergy: enhancement of 5-fluorodeoxyridylate binding to thymidylate synthase by dihydropteroylpolyglutamates | Q36408748 |
| | Schedule-dependent cytotoxicity of methotrexate and 5-fluorouracil in human colon and breast tumor cell lines | Q37024987 |
| | Biochemical modulation of 5-fluorouracil by PALA: mechanism of action | Q40750369 |
| | Biomodulation of Fluorouracil in colorectal cancer | Q40859206 |
| | Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line | Q41056508 |
| | Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells | Q41092839 |
| | Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer | Q41118750 |
| | Cytotoxicity of floxuridine and 5-fluorouracil in human T-lymphoblast leukemia cells: enhancement by leucovorin. | Q41355050 |
| | Enhanced 5-Fluorouracil Nucleotide Formation After Methotrexate Administration: Explanation for Drug Synergism | Q41760435 |
| | Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer | Q42134170 |
| | The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group | Q43427611 |
| | Biochemical modulation of 5-fluorouracil by PALA. | Q44156050 |
| | 5-Fluorouracil (FUra) and folinic acid (FA) therapy in patients with colorectal cancer | Q44948504 |
| | Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer | Q46328967 |
| | Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group | Q46925005 |
| | A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. | Q53553125 |
| | Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. | Q54642095 |
| | Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. | Q55067760 |
| | Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study | Q57758618 |
| | Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity | Q58290077 |
| | Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: A Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study | Q58614979 |
| | A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma | Q68130657 |
| | The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer | Q68207046 |
| | Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma | Q68588461 |
| | Phase I trial of PALA, methotrexate, fluorouracil, leucovorin, and uridine rescue in patients with advanced cancer. The use of uridine to decrease fluorouracil toxicity | Q68920739 |
| | Irinotecan is an active agent in untreated patients with metastatic colorectal cancer | Q71059673 |
| | Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer | Q71072643 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biochemistry | Q7094 |
| | colorectal cancer | Q188874 |
| | fluorouracil | Q238512 |
| P304 | page(s) | 9 | |
| P577 | publication date | 2002-05-02 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer--a phase II study | |
| P478 | volume | 2 | |